文献速递认知障碍与谵妄老年慢病共病管理

他汀类药物在痴呆患者中的获益与危害:系统综述与荟萃分析

Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Am Geriatr Soc · 2020-02-10

该系统综述纳入5篇研究,仅涉及阿尔茨海默型痴呆,未发现他汀对心血管事件或总体健康影响的证据。基于3项异质性队列研究,极低置信度提示他汀可能延缓痴呆进展;基于2项18个月随机对照试验,极低置信度提示不良事件无显著差异。证据不足以充分评估他汀在痴呆患者中的疗效。

要点

  • 证据仅覆盖阿尔茨海默型痴呆,缺乏其他痴呆类型数据。
  • 他汀对心血管事件和总体健康的影响无证据。
  • 极低置信度提示他汀可能小幅度延缓痴呆进展。

核心结论

  • 证据不足以充分评估他汀在痴呆患者中的疗效。
  • 极低置信度提示他汀可能小幅度延缓阿尔茨海默痴呆进展,但与既往较短随机试验结果矛盾。
  • 安全性方面,试验数据把握度不足,无法显示组间临床重要差异。

研究设计与样本

  • 系统综述纳入随机对照试验和观察性研究。
  • 检索PubMed、Web of Science和Cochrane试验数据库2007至2019年发达国家出版物。
  • 纳入所有类型痴呆、平均年龄大于65岁、他汀治疗6个月及以上的研究。
  • 共5篇文章符合纳入标准,仅报告阿尔茨海默型痴呆。

主要发现

  • 无关于心血管事件或总体健康的证据。
  • 基于3项异质性队列研究,极低置信度发现他汀减少痴呆进展。

关键数值与推荐

  • 纳入研究平均年龄大于65岁,他汀治疗至少6个月。
  • 主要结局为2年时主要不良心血管事件、痴呆进展和总体健康,或任何时间药物不良事件。

临床怎么用

  • 临床决策时应认识到他汀在痴呆患者中的证据不足。
  • 建议利用临床数据开展进一步观察性研究以指导处方决策。

局限性

  • 仅5篇文章符合纳入标准,且仅涉及阿尔茨海默型痴呆。
  • 队列研究异质性大,证据置信度极低。
  • 随机对照试验数据把握度不足,无法显示临床重要差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: More people with dementia also fall into the category of high vascular risk, for which a statin is usually prescribed. However, these recommendations are based on studies in people without dementia. We aimed to evaluate the evidence for the long-term effectiveness and harm of statin therapy in patients with dementia. DESIGN: Systematic review of randomized controlled trials and observational research. SETTING: Publications from developed countries indexed in the PubMed, Web of Science, and Cochrane trial database between 2007 and 2019. PARTICIPANTS: Trials including people with all types of dementia with a mean age older than 65 years. INTERVENTION: Treatment with a statin for 6 months or longer. MEASUREMENTS: Major adverse cardiovascular events, dementia progression, and general health at 2 years, or medication adverse events (AEs) at any time. Each article was assessed for bias using the Newcastle-Ottawa or Cochrane Collaboration tools. A narrative synthesis and pooled analyses are reported. RESULTS: Five articles met the inclusion criteria. They reported only on dementia of the Alzheimer's type. There was no evidence regarding cardiovascular events or general health. We made a very low confidence finding that statins reduce dementia progression based on three cohort studies of heterogeneous design. We made a very low confidence finding of no significant difference in AEs based on two randomized controlled trials of 18 months: odds ratios of any AE = 1.21 (95% confidence interval [CI] = .83-1.77), serious AE = 1.03 (95% CI = .76-1.87), and death = 1.69 (95% CI = .79-3.62). CONCLUSION: Evidence was insufficient to fully evaluate the efficacy of statins in people with dementia. We found that statins may have a small benefit delaying progression in Alzheimer's dementia, although this conflicted with previous findings from shorter randomized trials. For safety, the trial data lacked power to show clinically important differences between the groups. We recommend that clinical data be leveraged for further observational studies to inform prescribing decisions. J Am Geriatr Soc 68:650-658, 2020.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Davis KAS, Bishara D, Perera G, et al. Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2020. PMID: 32039479. doi:10.1111/jgs.16342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。